OR WAIT null SECS
June 18, 2015.
GSK is investing over $95m in new technologies and approaches for decoding how genes are controlled and how a cell’s “operating system” functions. The drug maker's investment will help launch the Altius Institute for Biomedical Sciences (Seattle, WA), which will be led by Dr John A. Stamatoyannopoulos, Professor of Genome Sciences and Medicine at the University of Washington School of Medicine.
GSK and Altius have signed a 10-year collaboration agreement that provides long-term support for innovative, high-impact research.